Online first
Artykuł przeglądowy
Opublikowany online: 2025-02-26
Wyświetlenia strony
90
Wyświetlenia/pobrania artykułu
10
Diagnostyka molekularna i leczenie raka płuca u osób niepalących
Streszczenie
Rak płuca jest najczęstszą przyczyną zgonów nowotworowych na całym świecie. W Polsce umiera z tego powodu co roku około
22 tysięcy osób. Ponad 80% raków płuca związanych jest z paleniem tytoniu, ale wśród ogółu zachorowań na ten nowotwór rośnie
udział osób nigdy niepalących (lung cancer in never smokers, LCINS). W Europie Zachodniej i USA trend ten dotyczy obydwu
płci, natomiast w Polsce jedynie mężczyzn, gdyż tylko w tej grupie nastąpił znaczący spadek liczby palaczy tytoniu. Szacuje się,
że LCINS był w 2023 roku piątą najczęstszą przyczyną zgonów nowotworowych na świecie. Wraz z rosnącym udziałem LCINS,
kluczowe staje się zrozumienie charakterystyki nowotworów u osób niepalących oraz odmienności w ich diagnostyce i leczeniu.
Badania z ostatnich lat dostarczają istotnych informacji na temat cech molekularnych LCINS oraz wynikających z nich implikacji
terapeutycznych. W niniejszym artykule omówiono aktualną wiedzę na ten temat oraz wyniki najważniejszych badań dotyczących
leków ukierunkowanych molekularnie.
Słowa kluczowe: rak płuca u niepalącychdiagnostyka molekularnaterapia celowanasekwencjonowanie kolejnej generacji
Referencje
- Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024; 74(3): 229–263.
- Dai X, Gakidou E, Lopez AD. Evolution of the global smoking epidemic over the past half century: strengthening the evidence base for policy action. Tob Control. 2022; 31(2): 129–137.
- Jeon J, Holford TR, Levy DT, et al. Smoking and Lung Cancer Mortality in the United States From 2015 to 2065: A Comparative Modeling Approach. Ann Intern Med. 2018; 169(10): 684–693.
- Couraud S, Zalcman G, Milleron B, et al. Lung cancer in never smokers--a review. Eur J Cancer. 2012; 48(9): 1299–1311.
- LoPiccolo J, Gusev A, Christiani DC, et al. Lung cancer in patients who have never smoked - an emerging disease. Nat Rev Clin Oncol. 2024; 21(2): 121–146.
- Rait G, Horsfall L. Twenty-year sociodemographic trends in lung cancer in non-smokers: A UK-based cohort study of 3.7 million people. Cancer Epidemiol. 2020; 67: 101771.
- Subramanian J, Govindan R. Lung cancer in never smokers: a review. J Clin Oncol. 2007; 25(5): 561–570.
- Khuder SA. Effect of cigarette smoking on major histological types of lung cancer: a meta-analysis. Lung Cancer. 2001; 31(2-3): 139–148.
- Friedlaender A, Perol M, Banna GL, et al. Oncogenic alterations in advanced NSCLC: a molecular super-highway. Biomark Res. 2024; 12(1): 24.
- Riely GJ, Kris MG, Rosenbaum D, et al. Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma. Clin Cancer Res. 2008; 14(18): 5731–5734.
- Planchard D, Besse B. Lung cancer in never-smokers. Eur Respir J. 2015; 45(5): 1214–1217.
- Norum J, Nieder C. Tobacco smoking and cessation and PD-L1 inhibitors in non-small cell lung cancer (NSCLC): a review of the literature. ESMO Open. 2018; 3(6): e000406.
- Zhang T, Joubert P, Ansari-Pour N, et al. Genomic and evolutionary classification of lung cancer in never smokers. Nat Genet. 2021; 53(9): 1348–1359.
- Wang X, Ricciuti B, Nguyen T, et al. Association between Smoking History and Tumor Mutation Burden in Advanced Non-Small Cell Lung Cancer. Cancer Res. 2021; 81(9): 2566–2573.
- Alexandrov LB, Ju YS, Haase K, et al. Mutational signatures associated with tobacco smoking in human cancer. Science. 2016; 354(6312): 618–622.
- Mosele MF, Westphalen CB, Stenzinger A, et al. Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group. Ann Oncol. 2024; 35(7): 588–606.
- Choudhury NJ, Lavery JA, Brown S, et al. AACR GENIE BPC Core Team. The GENIE BPC NSCLC Cohort: A Real-World Repository Integrating Standardized Clinical and Genomic Data for 1,846 Patients with Non-Small Cell Lung Cancer. Clin Cancer Res. 2023; 29(17): 3418–3428.
- Mateo J, Chakravarty D, Dienstmann R, et al. A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT). Ann Oncol. 2018; 29(9): 1895–1902.
- Penault-Llorca F, Kerr KM, Garrido P, et al. Expert opinion on NSCLC small specimen biomarker testing - Part 1: Tissue collection and management. Virchows Arch. 2022; 481(3): 335–350.
- Chen H, Luthra R, Goswami RS, et al. Analysis of Pre-Analytic Factors Affecting the Success of Clinical Next-Generation Sequencing of Solid Organ Malignancies. Cancers (Basel). 2015; 7(3): 1699–1715.
- Tomasik B, Skrzypski M, Bieńkowski M, et al. Current and future applications of liquid biopsy in non-small-cell lung cancer-a narrative review. Transl Lung Cancer Res. 2023; 12(3): 594–614.
- Pascual J, Attard G, Bidard FC, et al. ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group. Ann Oncol. 2022; 33(8): 750–768.
- Gray JE, Markovets A, Reungwetwattana T, et al. Longitudinal Analyses of Circulating Tumor DNA for the Detection of EGFR Mutation-Positive Advanced NSCLC Progression During Treatment: Data From FLAURA and AURA3. J Thorac Oncol. 2024; 19(11): 1525–1538.
- Remon J, Besse B, Aix SP, et al. Osimertinib treatment based on plasma T790M monitoring in patients with EGFR-mutant non-small-cell lung cancer (NSCLC): EORTC Lung Cancer Group 1613 APPLE phase II randomized clinical trial. Ann Oncol. 2023; 34(5): 468–476.
- Vitale A, Mastrantoni L, Russo J, et al. Impact of Comprehensive Genome Profiling on the Management of Advanced Non-Small Cell Lung Cancer: Preliminary Results From the Lung Cancer Cohort of the FPG500 Program. JCO Precis Oncol. 2024; 8: e2400297.
- Chang JC, Rekhtman N. Pathologic Assessment and Staging of Multiple Non-Small Cell Lung Carcinomas: A Paradigm Shift with the Emerging Role of Molecular Methods. Mod Pathol. 2024; 37(5): 100453.
- Paver E, O'Toole S, Cheng XM, et al. Updates in the molecular pathology of non-small cell lung cancer. Semin Diagn Pathol. 2021; 38(5): 54–61.
- Hendriks LEL, Remon J, Faivre-Finn C, et al. Non-small-cell lung cancer. Nat Rev Dis Primers. 2024; 10(1): 71.
- Chrzanowska NM, Kowalewski J, Lewandowska MA. Use of Fluorescence In Situ Hybridization (FISH) in Diagnosis and Tailored Therapies in Solid Tumors. Molecules. 2020; 25(8).
- Bernard PS, Wittwer CT. Real-time PCR technology for cancer diagnostics. Clin Chem. 2002; 48(8): 1178–1185.
- Mardis ER, Wilson RK. Cancer genome sequencing: a review. Hum Mol Genet. 2009; 18(R2): R163–R168.
- Horak P, Fröhling S, Glimm H. Integrating next-generation sequencing into clinical oncology: strategies, promises and pitfalls. ESMO Open. 2016; 1(5): e000094.
- Hsu WH, Yang JCH, Mok TS, et al. Overview of current systemic management of EGFR-mutant NSCLC. Ann Oncol. 2018; 29(suppl_1): i3–i9.
- Karachaliou N, Fernandez-Bruno M, Bracht JW, et al. EGFR first- and second-generation TKIs-there is still place for them in -mutant NSCLC patients. Transl Cancer Res. 2019; 8(Suppl 1): S23–S47.
- Watanabe K, Hosomi Y, Naoki K, et al. The Whole Picture of First-Line Osimertinib for EGFR Mutation-Positive Advanced NSCLC: Real-World Efficacy, Safety, Progression Pattern, and Posttreatment Therapy (Reiwa Study). JTO Clin Res Rep. 2024; 5(11): 100720.
- Soria JC, Ohe Y, Vansteenkiste J, et al. FLAURA Investigators. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. N Engl J Med. 2018; 378(2): 113–125.
- Passaro A, Wang J, Wang Y, et al. MARIPOSA-2 Investigators. Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study. Ann Oncol. 2024; 35(1): 77–90.
- Yang JCH, Schuler M, Popat S, et al. Afatinib for the Treatment of NSCLC Harboring Uncommon EGFR Mutations: A Database of 693 Cases. J Thorac Oncol. 2020; 15(5): 803–815.
- Bar J, Peled N, Schokrpur S, et al. UNcommon EGFR Mutations: International Case Series on Efficacy of Osimertinib in Real-Life Practice in First-LiNe Setting (UNICORN). J Thorac Oncol. 2023; 18(2): 169–180.
- Zhou C, Tang KJ, Cho BC, et al. PAPILLON Investigators. Amivantamab plus Chemotherapy in NSCLC with Exon 20 Insertions. N Engl J Med. 2023; 389(22): 2039–2051.
- Peters S, Camidge DR, Shaw AT, et al. ALEX Trial Investigators. Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2017; 377(9): 829–838.
- Camidge DR, Kim HR, Ahn MJ, et al. Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2018; 379(21): 2027–2039.
- Solomon BJ, Liu G, Felip E, et al. Lorlatinib Versus Crizotinib in Patients With Advanced -Positive Non-Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study. J Clin Oncol. 2024; 42(29): 3400–3409.
- Drilon A, Chiu CH, Fan Y, et al. Long-Term Efficacy and Safety of Entrectinib in Fusion-Positive NSCLC. JTO Clin Res Rep. 2022; 3(6): 100332.
- Liu SV, Frohn C, Minasi L, et al. Real-world outcomes associated with afatinib use in patients with solid tumors harboring NRG1 gene fusions. Lung Cancer. 2024; 188: 107469.
- Planchard D, Sanborn RE, Negrao MV, et al. BRAF-mutant metastatic NSCLC: disease overview and treatment landscape. NPJ Precis Oncol. 2024; 8(1): 90.
- Subbiah V, Wolf J, Konda B, et al. Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial. Lancet Oncol. 2022; 23(10): 1261–1273.
- Griesinger F, Curigliano G, Thomas M, et al. Safety and efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial. Ann Oncol. 2022; 33(11): 1168–1178.
- Wolf J, Seto T, Han JY, et al. GEOMETRY mono-1 Investigators. Capmatinib in Exon 14-Mutated or -Amplified Non-Small-Cell Lung Cancer. N Engl J Med. 2020; 383(10): 944–957.
- Paik PK, Felip E, Veillon R, et al. Tepotinib in Non-Small-Cell Lung Cancer with Exon 14 Skipping Mutations. N Engl J Med. 2020; 383(10): 931–943.
- Ferrari G, Del Rio B, Novello S, et al. HER2-Altered Non-Small Cell Lung Cancer: A Journey from Current Approaches to Emerging Strategies. Cancers (Basel). 2024; 16(11).
- Li BT, Smit EF, Goto Y, et al. DESTINY-Lung01 Trial Investigators. Trastuzumab Deruxtecan in -Mutant Non-Small-Cell Lung Cancer. N Engl J Med. 2022; 386(3): 241–251.
- Dearden S, Stevens J, Wu YL, et al. Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap). Ann Oncol. 2013; 24(9): 2371–2376.
- Mok T, Yao W, Duruisseaux M, et al. KRYSTAL-12: Phase 3 study of adagrasib versus docetaxel in patients with previously treated advanced/metastatic non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation. Journal of Clinical Oncology. 2024; 42(17_suppl): LBA8509–LBA8509.
- Repetto M, Chiara Garassino M, Loong HH, et al. NTRK gene fusion testing and management in lung cancer. Cancer Treat Rev. 2024; 127: 102733.
- Schram A, Goto K, Kim DW, et al. 1315MO Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion-positive (NRG1+) non-small cell lung cancer (NSCLC). Annals of Oncology. 2023; 34: S756–S757.
- Dai L, Jin Bo, Liu T, et al. The effect of smoking status on efficacy of immune checkpoint inhibitors in metastatic non-small cell lung cancer: A systematic review and meta-analysis. EClinicalMedicine. 2021; 38: 100990.
- Zhao Yi, He Y, Wang W, et al. Efficacy and safety of immune checkpoint inhibitors for individuals with advanced EGFR-mutated non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitors: a systematic review, meta-analysis, and network meta-analysis. Lancet Oncol. 2024; 25(10): 1347–1356.
